← Eichor
Condition: Drug Resistant Tuberculosis Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Drug Resistant Tuberculosis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia
Phase N/A · 1 location(s) · University of Namibia · NCT05022238Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
Phase 2/Phase 3 · 6 location(s) · University of California, San Francisco · NCT06441006Novel Triple-dose Tuberculosis Retreatment Regimen
Phase 3 · 1 location(s) · Institute of Tropical Medicine, Belgium · NCT04260477Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
NA · 1 location(s) · University of California, San Francisco · NCT05553236Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of M
Phase 2 · 11 location(s) · Janssen Research & Development, LLC · NCT02354014Training Protocol on the Natural History of Tuberculosis
Phase N/A · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT01212003Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
NA · 5 location(s) · Johns Hopkins University · NCT05671718A PAN-USR TB Multi-Center Trial
Phase 3 · 3 location(s) · Shenzhen Third People's Hospital · NCT06905522An Adaptive Randomized Controlled Trial
NA · 1 location(s) · Columbia University · NCT05633056Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) Durin
Phase 4 · 1 location(s) · Marco Schiuma · NCT07477119A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
Phase 3 · 35 location(s) · Otsuka Pharmaceutical Development & Commercialization, Inc. · NCT07209761Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
NA · 1 location(s) · Albert Einstein College of Medicine · NCT06590428
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.